​

IDEXX Laboratories (IDXX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

IDXX Stock Forecast

IDEXX Laboratories (IDXX) stock forecast, based on 23 Wall Street analysts, predicts a 12-month average price target of $665.00, with a high of $710.00 and a low of $620.00. This represents a 29.09% increase from the last price of $515.15.

$400 $470 $540 $610 $680 $750 High: $710 Avg: $665 Low: $620 Last Closed Price: $515.15

IDXX Stock Rating

IDEXX Laboratories stock's rating consensus is Buy, based on 23 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (56.52%), 9 Hold (39.13%), 1 Sell (4.35%), and 0 Strong Sell (0.00%).

Buy
Total 23 0 1 9 13 Strong Sell Sell Hold Buy Strong Buy

IDXX Price Target Upside V Benchmarks

TypeNameUpside
StockIDEXX Laboratories29.09%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks7.61%

Price Target Trends

1M3M12M
# Anlaysts1216
Avg Price Target$710.00$665.00$755.94
Last Closing Price$515.15$515.15$515.15
Upside/Downside37.82%29.09%46.74%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26445-114
Aug, 26455-115
Jul, 26455-115
Jun, 26455-115
May, 26455-115
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 11, 2026Glen SantangeloBarclays$710.00$595.7619.18%37.82%
Jul 27, 2026UBS$620.00$559.8610.74%20.35%
Apr 28, 2026Andrea AlfonsoUBS$640.00$569.1712.44%24.24%
Feb 09, 2026Piper Sandler$750.00$644.6116.35%45.59%
Feb 05, 2026Glen SantangeloBarclays$800.00$642.9424.43%55.29%
Feb 03, 2026Andrea AlfonsoUBS$730.00$639.6014.13%41.71%
Feb 03, 2026BTIG$800.00$639.6025.08%55.29%
Dec 08, 2025Glen SantangeloBarclays$850.00$706.6520.29%65.00%
Nov 04, 2025Morgan Stanley$805.00$721.0411.64%56.27%
Nov 04, 2025UBS$750.00$722.943.74%45.59%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 11, 2026BarclaysOverweightOverweighthold
Aug 05, 2026CitigroupNeutralNeutralhold
Apr 28, 2026UBSNeutralNeutralhold
Apr 15, 2026CitigroupBuyNeutralinitialise
Feb 05, 2026BarclaysOverweightOverweighthold
Feb 03, 2026UBSNeutralNeutralhold
Dec 08, 2025BarclaysOverweightOverweightinitialise
Nov 04, 2025Morgan StanleyOverweightOverweighthold
Nov 04, 2025UBSNeutralNeutralhold
Nov 04, 2025BTIGBuyBuyhold

Financial Forecast

EPS Forecast

$7 $9 $11 $13 $15 $17 $18 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.74$8.12$10.17$10.77$13.17---
Avg Forecast$8.38$7.91$9.86$10.46$11.97$13.55$15.48$16.93
High Forecast$8.50$7.99$9.92$10.54$12.22$14.03$16.33$17.13
Low Forecast$8.30$7.82$9.81$10.40$11.75$12.84$14.21$16.70
Surprise %4.30%2.65%3.14%2.96%10.03%---

Revenue Forecast

$3B $4B $4B $5B $5B $6B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.22B$3.37B$3.66B$3.90B$4.30B---
Avg Forecast$3.19B$3.36B$3.65B$3.88B$4.15B$4.51B$4.95B$5.39B
High Forecast$3.23B$3.38B$3.66B$3.89B$4.18B$4.52B$4.95B$5.44B
Low Forecast$3.17B$3.33B$3.64B$3.84B$4.12B$4.50B$4.94B$5.34B
Surprise %0.65%0.28%0.33%0.49%3.60%---

Net Income Forecast

$450M $650M $850M $1B $1B $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$744.85M$679.09M$845.04M$887.87M$1.06B---
Avg Forecast$604.02M$662.67M$845.04M$878.93M$1.01B$1.10B$1.22B$1.42B
High Forecast$724.83M$795.20M$1.01B$884.81M$1.03B$1.18B$1.37B$1.44B
Low Forecast$483.22M$530.13M$676.03M$873.04M$986.97M$1.08B$1.19B$1.40B
Surprise %23.31%2.48%-1.02%5.25%---

IDXX Forecast FAQ

Is IDEXX Laboratories stock a buy?

IDEXX Laboratories stock has a consensus rating of Buy, based on 23 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 9 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that IDEXX Laboratories is a favorable investment for most analysts.

What is IDEXX Laboratories's price target?

IDEXX Laboratories's price target, set by 23 Wall Street analysts, averages $665 over the next 12 months. The price target range spans from $620 at the low end to $710 at the high end, suggesting a potential 29.09% change from the previous closing price of $515.15.

How does IDEXX Laboratories stock forecast compare to its benchmarks?

IDEXX Laboratories's stock forecast shows a 29.09% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the diagnostics & research stocks industry (7.61%).

What is the breakdown of analyst ratings for IDEXX Laboratories over the past three months?

  • September 2026: 28.57% Strong Buy, 28.57% Buy, 35.71% Hold, 0% Sell, 7.14% Strong Sell.
  • August 2026: 26.67% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 6.67% Strong Sell.
  • July 2026: 26.67% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 6.67% Strong Sell.

What is IDEXX Laboratories’s EPS forecast?

IDEXX Laboratories's average annual EPS forecast for its fiscal year ending in December 2026 is $13.55, marking a 2.89% increase from the reported $13.17 in 2025. Estimates for the following years are $15.48 in 2027, and $16.93 in 2028.

What is IDEXX Laboratories’s revenue forecast?

IDEXX Laboratories's average annual revenue forecast for its fiscal year ending in December 2026 is $4.51B, reflecting a 4.84% increase from the reported $4.3B in 2025. The forecast for 2027 is $4.95B, and $5.39B for 2028.

What is IDEXX Laboratories’s net income forecast?

IDEXX Laboratories's net income forecast for the fiscal year ending in December 2026 stands at $1.1B, representing an 4.04% increase from the reported $1.06B in 2025. Projections indicate $1.22B in 2027, and $1.42B in 2028.